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Given  the multi-factorial  nature  of  cancer,  uncovering  its  metabolic  alterations  and  evaluating  their  impli-
cations is  a  major  challenge  in  biomedical  sciences  that will help  in  the  optimal  design  of  personalized
treatments.  The  advance  of  high-throughput  technologies  opens  an  invaluable  opportunity  to  monitor
the  activity  at diverse  biological  levels  and  elucidate  how  cancer  originates,  evolves  and  responds  under
drug  treatments.  To  this  end, researchers  are  confronted  with  two  fundamental  questions:  how  to inter-
pret  high-throughput  data  and  how  this  information  can  contribute  to  the  development  of personalized
treatment  in  patients.  A  variety  of  schemes  in systems  biology  have  been  suggested  to characterize  the
phenotypic  states  associated  with  cancer  by utilizing  computational  modeling  and  high-throughput  data.
These theoretical  schemes  are  distinguished  by  the level  of  complexity  of the  biological  mechanisms  that
they represent  and  by  the  computational  approaches  used  to simulate  them.  Notably,  these  theoreti-
cal  approaches  have  provided  a proper  framework  to explore  some  distinctive  metabolic  mechanisms
observed  in cancer  cells  such  as  the  Warburg  effect.  In this  review,  we focus  on  presenting  a general
view  of  some  of  these  approaches  whose  application  and  integration  will  be  crucial  in  the  transition  from
local  to global  conclusions  in  cancer  studies.  We  are  convinced  that  multidisciplinary  approaches  are
required  to construct  the  bases  of  an  integrative  and  personalized  medicine,  which  has  been  and  remains
a  fundamental  task  in  the  medicine  of this  century.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Multiple roads lead to cancer, it can emerge as the result of
utations in regulatory or signaling proteins [1], as well as the
mbalance of oxidative stress and anti-oxidative mechanisms [2],
r by the continuous exposition of cells to a given stimulus [3].
here are a myriad of causes for cancer, and the compounds or
onditions that stop or delay its progress in some circumstances do
ot work in others. A variety of factors contribute to this complex
ehavior, including the heterogeneity in cancer cell populations,
ven in tumors from the same patient, a fact that directly reduces
he effectiveness and reliability of the drugs for treating the disease
4,5]. Furthermore, with the advent of high-throughput (HT) and
ext Generation Sequencing (NGS) technologies, new biological
echanisms that are typical of cancer cells have been discovered
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[6]. This scenery has created the need to develop new ways to inter-
pret these data and elucidate their role in human diseases in a
coherent and systematic fashion. At this stage, a biological system
can be considered an interactive set of networks with components
and relations at different biological levels that are the causes by
which certain phenotype, functional or dysfunctional, emerges, see
Fig. 1.
Currently, understanding how these biological networks
orchestrate their activities to support cancer phenotypes is a
great challenge in medical science to prevent, suggest and predict
strategies with direct implications in clinical stages. Despite this
astonishing complexity – which involves biological processes such
as signaling, regulation and metabolic networks, – hallmark traits
have been suggested to characterize key processes in all human
cancers, such as proliferation, invasion and metastasis [1,7,8].Arguably the most fundamental trait of cancer cells is their abil-
ity to sustain chronic uncontrolled proliferation [1]. Although it is
well accepted that this dysfunctional state is accompanied by a
rewiring of metabolic activity in the cell [9], it is not completely
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Mechanisms of metabolic regulation in cancer cells. Cancer cells display a variety of alterations in metabolic pathways for building the precursors that cells need
to  proliferate and sustain the anomalous state. Glycolysis, the TCA cycle and glutaminolysis, are a few pathways that guide the malignant transformation by covering the
metabolic demand of nucleotides, amino acids, lipids and other building materials that cancer cells need to proliferate. Enzymes with an important role in cancer are depicted
in  the upper level of the ﬁgure (gray ovals), and metabolites participating in anabolic pathways are depicted in pink and orange arrows. These metabolic alterations are
modulated by a variety of mechanisms that involve other molecules, such as oncogenes, tumor suppressors and microRNAs. Examples falling in the ﬁrst category are given by
c-MYC,  HIF-1 and P53, with activities that directly affect metabolic activity (green circles). c-Myc and HIF act in complexes with other proteins to modulate the expression of
glycolytic genes or enzymes. c-Myc speciﬁcally stimulates glutaminolysis. P53 regulates the suppression of glycolysis through TIGAR and increases mitochondrial metabolism
via  SCO2 (yellow circle), as depicted by the dashed blue arrows. In turn, these regulators modulate the expression of other target genes to enhance the cancer phenotype.
c-MYC  and HIF-1 promote the expression of cell cycle proteins, and mutations in P53, denoted as P53*, inhibit apoptotic genes, as depicted by the dashed green arrows.
Moreover, the transcription of oncogenes and tumor suppressors can be controlled by the up-regulation of oncogenic miRNAs (red) or inhibitory miRNAs, see green arrows.
Simultaneously, metabolites can play an important role in epigenetic regulation, see yellow arrow. Furthermore, the stromal cells induce important metabolic changes to favor
cancer  proliferation thought metabolic cross-talk (cyan arrow). GLUT1 – Glucose transporter 1, HK-hexokinase, GLC – Glucose, G6P – Glucose-6 phosphate, F6P – Fructose
1,6phosphate, PFK – Phosphofructokinase, G3P – Glyceraldehyde-3phosphate, 3PG – 3-Phosphoglycerate, PEP – Phosphoenol pyruvate, LDH – Lactate dehydrogenase, PYR –
P xylate
C , SUC –
c
a
t
gyruvate, LAC – Lactate, MCT1 – Monocarboxylate transporter 1, MCT4 – Monocarbo
IT  – Citrate, ICIT – Isocitrate, -KG--Ketoglutarate, SuCoA – Succinylcoenzyme A
lear how and which metabolic pathways differentially alters their
ctivities in cancer versus normal tissues [10,11].
The most studied metabolic alteration in cancer is the degrada-
ion of glucose via aerobic glycolysis, a less efﬁcient pathway for
enerating ATP compared with oxidative phosphorylation, despite transporter 4, SLC1A5 – Glutamine transporter, GLN–Glutamine, GLU – Glutamate,
 Succinate, FUM – Fumarate, MAL  – Malate.
oxygen availability. This ﬁnding was reported almost a century ago
by Otto Warburg in his seminal studies of metabolism in cancer
cells [12]. Notably, studies in cancer biology have demonstrated
that cancer genes are intimately linked to the Warburg effect and
other metabolic alterations [13,14], see Fig. 1. There is evidence
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hat reprogramming signaling or regulatory networks in normal
ells induces the expression and activation of several enzymes that
orm part of the metabolic pathways that promote proliferation
nd survival in cancer cells [15–17]. For instance, c-Myc regu-
ates the expression of glycolytic genes, particularly enzymes such
s hexokinase (HK), phosphofructokinase (PFK), lactate dehydro-
enase A (LDHA) and extracellular glucose transporter [18–20].
urthermore, c-Myc controls glutaminolytic pathways that pro-
ote the expression of glutamine transporters such as SLC1A5
nd the expression of glutaminase (GLS) [21]. c-Myc has also been
mplicated in the regulation of genes participating in mitochondrial
iogenesis [22]. Similarly, HIF-1 modulates the activity of some
nzymes involved in glycolytic metabolism at hypoxic conditions
23,24]. Moreover, mutations in many types of cancer disrupt the
unctional role of some tumor suppressors. For example, mutations
n P53 simultaneously promote glycolysis and inhibit mitochon-
rial respiration in cancer cells through genes such as TIGAR [25]
nd SCO2 [26], see Fig. 1.c-Myc, HIF-1 and P53 are together involved
n other biological processes that sustain cancer. c-Myc and HIF-
 form a complex with the protein MAX, and consequently, this
omplex up-regulates the expression of cyclins (proteins involved
n of cell cycle). Conversely, mutated P53 promotes cancer by
own-regulating apoptotic genes [24,27]. In turn, the transcription
actors mentioned above are regulated by microRNAs (miRNAs),
mall-noncoding RNAs of 18–25 nucleotides in length [28]. miRNAs
ypically reduce the translation and stability of target mRNAs by
peciﬁc base-pairing interactions, but in some cases, they can pro-
ote translation by indirect mechanisms [28–30]. Some elements
f metabolic networks can affect other levels of regulation, which
dds another layer of complexity; for example, there is evidence
hat metabolites can play an important role in epigenetic regula-
ion [31], see Fig. 1. The above examples represent only a small
raction of many cross-linking interactions at different biological
evels that are together responsible for cancer phenotype.
These different levels of biological information constitute one
spect that determines metabolic capabilities in cancer cells, how-
ver the microenvironment also plays a relevant role in supporting
ancer phenotypes. Epithelial cancer cells have been shown to
nduce a type of aerobic glycolysis in neighboring ﬁbroblasts [32].
he proposed mechanism considers that cancer associated ﬁbro-
lasts (CAF) produce high-energy metabolites such as lactate and
xport them to the microenvironment. Then, epithelial cancer cells
an use these metabolites to fuel mitochondrial activity. This bio-
hemical crosstalk between cell types is called the reverse Warburg
ffect and induces a higher proliferative capacity in epithelial can-
er cells [32]. These ﬁndings reveal that the classical Warburg Effect
nd the reverse Warburg effect are only the top of the iceberg on
etabolic alterations in cancer; there is thus an increased need
o understand how metabolic pathways in cancer can be altered
y environmental cells in a tissue speciﬁc context. To construct
 holistic view of this phenomenon, it is necessary to develop
ystemic schemes capable of simultaneously: (1) representing bio-
ogical knowledge in a mathematical language; (2) integrating HT
ata; and (3) formulating and assessing metabolic predictions in
ilico [33].
Signiﬁcant advances have been reported in understanding can-
er metabolism through two parallel branches: experimentally
nd computationally. A variety of biological assays in cancer
ave discovered new metabolic changes that support growth and
roliferation [10,34–37]. Additionally, new theoretical schemes
ave been suggested to analyze, describe and predict cellular
etabolism at a genome scale level [38]. Although both branches
ave been evolving, there remains a signiﬁcant challenge in
ntegrating them and improving our understanding of cancer
etabolism. In this review, we present some of the standard
ormalisms to approach this problem. These methods represent Cancer Biology 30 (2015) 79–87 81
a cornerstone for quantitatively interpreting and understanding
how cells alter their metabolism to acquire their malignant pheno-
type, an aim that could have strong implications for the design of
combined medical treatments in cancer that achieve more efﬁcient
results [39–41].
1.1. Conceptual schemes in cancer systems biology
Complexity in cancer is astonishing, and understanding the
metabolic mechanisms involved in this disease requires qualitative
and quantitative methods for systematically elucidating their prin-
ciples [42–45]. To this end, a variety of theoretical frameworks have
been suggested in the literature. These frameworks can be classi-
ﬁed into a few categories: Topological, classical, stochastic, Boolean
and Constraint-based modeling, see Table 1. Although there is no
rule for the selection of the approach, it can be guided by at least
two criteria: (1) the type of biological question to be addressed;
and (2) the information that is available for the biological system.
In this section, we present some examples of different formalisms
that one can ﬁnd in the literature to analyze pathways in cancer.
This formalism represents schemes that are capable of uncovering
and highlighting some mechanisms in cancer at diverse levels of
detail and complexity.
2. Balancing complexity, biological detail and physiological
knowledge in cancer modeling
Given the complexity of biological systems, mathematical mod-
els are invaluable tool for integrating knowledge, understanding
mechanisms and predicting phenotypic behavior. In the construc-
tion of a model the balance between the degree of complexity and
the biological detail required should be addressed, Fig. 2. The strat-
egy is guided by criteria such as the nature of the question and the
available data to validate the outputs and predictions of the model.
A variety of schemes have been applied to explore the behavior
of cancer cells in a broad spectrum of biological processes, such
as tumor growth, metabolism and treatment response [45–49]. To
classify these schemes is not a trivial task, however they can be dis-
tinguished in terms of the mathematical formalisms used, the level
of its biological detail and the scopes of their predictions. Consider-
ing these items, we  suggest the classiﬁcation in Table 1 in which at
least six approaches are identiﬁed: Topological, Classical, Boolean,
Stochastic, Constraint-Based and Hybrid modeling.
2.1. Networks topology: unveiling structural organization in
metabolic networks
Cancer is a network disease resulting from alterations at diverse
biological levels, and topological analysis is a primary strategy to
survey the organization of the biological components and how
dysfunctional mechanisms can emerge. Thus, topological proper-
ties such as robustness, centrality, modularity, motif discovery or
minimal path-length provide clues concerning how organization
in biological networks can be associated with functional states
[50–54].
Genome-scale metabolic reconstruction of human cells is a fast-
moving area in which a framework can be established to distinguish
functional and dysfunctional states associated with diseases [38].
For instance, the most current version of the human metabolic
reconstruction (Recon) contains approximately 7400 reactions of
human metabolism, representing 123 metabolic pathways with
experimental and bioinformatics evidence in human cells [55,56].
Notably, this curated metabolic reconstruction constitutes a com-
putational platform to explore in silico the metabolic phenotypes
that characterize human diseases, such as cancer, obesity, diabetes
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Table 1
Modeling approaches in systems with applications in cancer systems biology. This table summarizes some properties associated with each approach. The square colors in
the  ﬁrst column label approach classiﬁcation in concordance with Fig. 2.
Approach Description Characteristics Limitations Examples
Network topology Mathematical scheme to
uncover the organizing
principles in biological
network
This approach has been able to
elucidate organizing principles
in biology by taking into
account a large number of
biological entities
Topological analysis is
independent of time and
physiological context
Protein–Protein interaction
networks
Gene co-expression
networks
Classical models Basic models based on ODE
or PDE for analyzing
biological systems with few
parameters
Consider few parameters of the
system generally macroscopic
properties. Those parameters
are related by simple equations
The resolution of the
information is restricted to
the scale used for the
calculations
Lokta–Volterra
competition model
Gompertz growth rate
Boolean models Biological networks whose
components can be in one of
two states (0,1) and whose
dynamic are given by logical
rules
It is a proper framework to
analyze biological circuits
where parameters are not well
characterized
The computational cost
may  rise depending upon
the complexity of the
network
Transcriptional regulatory
networks
Signaling networks
Stochastic models Models describing
phenomena in a probabilistic
approach due to signiﬁcative
ﬂuctuations in the system
Eliminate the deterministic view of
the system and consider that noise
is  fundamental to drive the
phenotype of a biological circuit
Computational simulation is a
time consuming process, it
increases according the
number of component rises
Master equation systems
Cellular automaton models
Agent base models
Constraint-based models Models based on genomic
base information (omics
technologies) and
physiological information.
With the combination of the
omics information model can
be  built for exploring the
relationship between genotype
with phenotype.
The quality of the results
depends of the metabolic
reconstruction, which in
turn depend on available
omics data and
physiological information.
Flux balance analysis
Flux variability analysis
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aHybrid models Combine two or more type of
models and mixes different
levels of information.
These mode
detailed and
accurate wi
nd mental disorders. Given the relevance of this reconstruc-
ion, community strategies have recently been accomplished for
mproving data quality and, consequently, the predictive scope of
n silico models [55]. Although topology is independent of time
nd physiological context, this approach can elucidate the orga-
izing principles that govern biological functions in cells [57]. For
xample, the presence of functional modules has been reported
t different levels of biological information, ranging from regula-
ory to metabolic networks [58,59]. The concept of modules has variety of connotations: in gene expression analysis a mod-
le is understood as a co-expressed set of genes, whereas in a
etworks context, a module is a set of nodes that have strong
ig. 2. Theoretical approaches used in cancer modeling. This ﬁgure depicts some theo
ombining different levels of complexity and detail. Models that represent high biologica
he  left of the ﬁgure. Conversely, models that represent low biological level of complexity
re  in concordance with those in the classiﬁcation proposed in Table 1.ome more
e more
Some limitations can be
solved mixing models, but
instead others can appear.
Novel agent base models
Multi-scale models
interconnections among them, characterized by a high clustering
coefﬁcient [60]. Notably, although these concepts arise from dif-
ferent criteria, there have been some efforts to combine them and
explore their relationships [42,57,59]. One such approach is based
on the reconstruction of co-expression networks that allows to
study how genes coordinate their expression to sustain a speciﬁc
biological state [42,61–64]. These methods have been applied in
a variety of tissues to elaborate hypotheses and identify drug tar-
gets [65–70]. Notable observations have been made with this type
of analysis, such as the ﬁnding that up-regulated genes in lung
cancer present a high degree of connection and centrality [71].
Although the representation of biological data through networks
retical schemes that have been applied to analyze different aspects of cancer by
l complexity and a low level of detail (reduced number of variables) are located to
 and a high level of detail are located on the right side. The colors of the examples
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Table 2
Algorithms used to reconstruct tissue-speciﬁc metabolic networks. Different strategies have been used in the literature to construction of metabolic networks. These computational methods use a genome-scale reconstruction
and  high-throughput data for ﬁnding the most coherent sub-network and are more consistent with HT data. This table describes some distinctive properties associated with some of these methods (IMAT, INIT, mCADRE and
MBA).  Global properties on input data, the algorithm used, its classiﬁcation and some applications are listed in this table.
Method Input data Algorithm Method
classiﬁcation
Biological reconstructions
MBA  Generic metabolic reconstruction
Human curated tissue speciﬁc
pathways
transcriptomic, proteomic,
metabolomic
The human curated tissue speciﬁc pathways reactions are classiﬁed as high
probability core reaction (CH),and those reported by omics data as medium
probability core reactions (CM).The idea behind it is to ﬁnd a model that has all
the CH, a maximal CM with minimal amount of extra reactions to ﬁll the gaps.
These characteristics are represented in a score. Reactions are removed from a
generic model unless its exclusion prevent the activation of Chor reduces the
score. Given that the order in which reactions are removed might affect the
reconstruction, multiple candidate models are made. Then the reactions are
ranked according to the fraction of candidate models in which they were
present. Then a new model is made adding reactions accordingly to this rank
until a consistent model is reached
Heuristic Liver model General cancer
metabolism Hereditary
Leiomyomatosis and Renal-Cell
INIT  Generic metabolic reconstruction
Protein information
Optional
Metabolome
transcriptome
The proteome and/or transcriptome data is transformed to weights. Evidence
of  expression will give a positive weight while absence will give a negative
weight.
This enable to make a constraint based model optimization where the number
of ﬂux-carrying reactions associated with highly expressed enzymes is
maximized.
Unlike the others method If the metabolite is present in the tissue it allows a
small positive net accumulation
Mixed
integer-linear
problem (MILP)
16 cancer models like breast, cervical,
colorectal, prostate, thyroid, liver, lung.
70 normal tissue/cell type brain (3
structures each divided in different
kind of cells), stomach, skin, among
others
mCADRE Generic metabolic reconstruction
Transcriptome
Optional
metabolome
The expression data is used to infer genes (reactions) that are present or
absent. Those reactions that are constantly present in the samples form a core
that should be able to carry ﬂux. The rest of the genes then are ranked
according to a combination of expression data and topology. For example if a
reaction is connected to a highly expressed reaction with few others
connections it probably should be included in the model. Then the generic
network is pruned given that ranking, unless its exclusion inactive a core
reaction or doesn’t allow the cell to create key metabolites from glucose
Optimization
with topology
26 cancers including breast, lung,
ovary, pancreas, uterus, among others
100 normal tissue type including 30
distinct brain structures, kidney, ovary,
cervix, thyroid, among others
iMAT  Generic metabolic reconstruction
Proteome, transcriptomic
The proteome and/or transcriptome data is transformed to numerical weights.
Evidence of expression will give a positive weight while absence will give a
negative weight. This enable to make a constraint based model optimization
where the number of ﬂux-carrying reactions associated with highly expressed
enzymes is maximized. This algorithm assumes steady state, unlike INIT
Mixed
integer-linear
problem (MILP)
10 healthy tissues brain, heart, kidney,
liver, lung, pancreas, prostate, spleen,
skeletal muscle and thymus
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as contributed to understanding the organization of dysfunc-
ional pathways in cancer, some elements require more attention
o ensure proper interpretations. For instance, the topological anal-
sis of metabolic networks is usually performed with only one
ype of element as node, i.e. either reactions or metabolites, as a
onsequence, there is a loss of information in these approaches.
o overcome this fact, the representation of metabolism through
ipartite networks and the development of methods to explore
heir architecture are needed to uncover more general organizing
rinciples [72]. In a more general context, the proper networks rep-
esentation and coherent interpretation of heterogeneous HT data
s a major challenge in the ﬁeld, achieving that will advance our
nderstanding of cancer in at least two ways: (1) uncovering orga-
ization principles by which cancer cells response and evolve in
issues, and (2) applying this knowledge to contribute to the design
f optimal treatments for cancer. Both goals are closely linked to
he purposes of P4 medicine: predictive, preventive, personalized,
nd participatory [46].
.2. Classical mathematical models
In classical models of cancer, ordinary differential equations
ODE) or partial differential equations (PDE) play important roles
n describing processes in cancer. A myriad of ODE models have
nalyzed cancer from different points of view that range from
odeling the growth rate to calculating radiation doses in ther-
py [45]. In this classiﬁcation, we include all those models whose
escription is characterized by simplifying the biological system
hrough a reduced number of mathematical variables associated
ith biological macroscopic properties (such as cell growth). A
eminal example falling into this classiﬁcation is the Gompertz
odel that reproduces growth rate measurements of cancer cells
n vitro [73]. Some other models based on ODE focus on analyz-
ng drug responses in cancer cultures, which is an essential point
or the optimal design of therapeutic strategies [74]. A detailed
escription of these methods and a broader number of examples
an be found in the literature [45]. Although these schemes have
ontributed signiﬁcantly to understanding global mechanisms in
ancer – such as growth rate, angiogenesis or metastasis – they do
ot include detailed information regarding speciﬁc alterations in
ignaling, regulatory or metabolic networks underlying the pheno-
ype. To integrate this latter information one necessary step is to
ove toward genome-scale modeling, which allows us to explore
he relationship among topology, dynamic and biological function-
lity [42,75,76].
.3. Boolean models
Another option for mathematical modeling in cancer is the
oolean formalism, a proper scheme for analyzing the dynamic
ehavior of transcriptional regulatory (TRN) or signaling networks
ithout the need to include kinetic parameters of the processes
nvolved. Given a network, this approach assumes that the expres-
ion of each biological element can be in one of two states (zero
r one) whose selection depends on a set of Boolean rules deﬁned
y the state of the elements that regulate it. Hence, with network
opology and Boolean rules, the dynamic behavior of genes can be
btained by applying the rules at discrete intervals of time in a syn-
hronic or asynchronic fashion. As a result, the state of the entire
etwork changes at a discrete interval of time until it reaches a
xed or cyclic state associated with a phenotype state, known as an
ttractor [77,78]. To ensure a proper simulation, one should deﬁne
oolean rules in terms of physiological knowledge [79]; however,
his information is often absent, and the combinatory effects of
he possible mechanisms signiﬁcantly increase as a function of the
umber of regulators involved. Nevertheless, this approach is an Cancer Biology 30 (2015) 79–87
appealing formalism when one desires to explore global questions
about the dynamic organization of the network without an accurate
knowledge of mathematical parameters. In cancer studies, Boolean
networks have an important role to elucidate the mechanisms that
can sustain the cancer phenotype [81–83]. Hence, to characterize
the biological proﬁle in cancer, some methods applying a Boolean
scheme have explored the physiological states of transcriptional
regulatory networks (TRN) and its transition between normal and
dysfunctional states [80,81]. For instance, Fumiã et al. constructed
a regulatory protein network integrating signaling pathways rele-
vant in cancer and characterized its phenotypes through Boolean
states. The dynamic behavior of this network was  such that the
attractors identiﬁed were associated with one of these physio-
logical states: proliferative, quiescent or apoptotic. Furthermore,
gene mutation analysis carried out in silico evaluate the stability of
cancer’s attractors, and their simulations concluded that perturba-
tions in some nodes elicit transitions among physiological states.
Notably, this ﬁnding suggest the possibility of controlling the dis-
ease evolution through the proper selection of targets along the
network [82].
2.4. Stochastic models
Biological processes in cells are constantly subject to internal
ﬂuctuations that are induced by the fact that concentrations of
some reacting species, such as transcriptional factors or metabo-
lites, are extremely low inside the cell. Notably, biological circuits
have the ability to control this noise to favor certain phenotypic
states in cells according to the environmental conditions [83].
Noise functions at many levels of biological complexity, including
genetic regulatory mechanisms, metabolism and cell populations
[5,84,85]. Cancer cells are not excluded from this fundamental
effect, and a clear consequence is observed at a population level
where subspecies of cancer cells in a tumor coexist to potentially
favor and sustain the malignant phenotype [5]. To describe the con-
sequences that noise has on cell activity, a stochastic approach is
more convenient than a deterministic one is more convenient to
elucidate the cellular mechanism by which noise is controlled [86].
For simplicity, we subdivided stochastic models into two types:
those that involve master equations; and those based on com-
putational techniques such as cellular automaton or Monte Carlo
simulations. The ﬁrst scheme is frequently used to investigate ana-
lytically the statistical properties of biological circuits with a low
number of components in a homogenized mixture [86], where
as the second scheme overcomes these limits by computation-
ally simulating interacting cells and biological networks subjected
to diffusion and population effects. Thus, cellular automaton has
been a central piece of the in silico models developed to simulate
heterogeneities in tumors by considering vascularization, genetic
mutations, metabolism and other biological processes [87]. For
instance, computational models have simulated tumor growth in
a set of interacting cancer cells in three dimensional space, where
gradient effects of key metabolites, such as glucose or oxygen, play
important factors in determining the disease. Overall, computa-
tional and mathematical models are complementary strategies for
understanding the mechanisms by which cells regulate intrinsic
and extrinsic noise and exploring how these biological mechanisms
contribute to the cancer phenotype.
2.5. Constraint-based modeling
New HT technologies have contributed signiﬁcantly to move
toward the integration and coherent interpretation of biologi-
cal data. To this end, constraint-based modeling is a paradigm
in systems biology that uses a biochemical, genetic and genomic
(BiGG) knowledge base to explore the metabolic capabilities in
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icroorganism and human tissues [88–90]. Constraint-based mod-
ling integrates computational methods that contribute to link
he fundamental relationship between the genotype and the
henotype such as the identiﬁcation of gene essentiality in
icroorganisms [90]. One of the most applied methods is ﬂux bal-
nce analysis (FBA) that calculate the ﬂux through a metabolic
etworks that ensure an optimal production of a speciﬁc physiolog-
cal objective function, such as biomass production in a cell [91,92].
BA has been successful in exploring the metabolic capacities of
ancer cell lines and identifying potential enzymes with thera-
eutic applications [33,93]. Given that most human diseases have
onsequences in metabolic activity, constraint-based modeling is
onsidered a useful paradigm for understanding the mechanisms
nvolved in human diseases [56].
.6. Hybrid models
Computational or mathematical models based on previous
chemes have guided our understanding of cancer at different lev-
ls of descriptions [44]. However, each approach has limits and to
ove toward more realistic models, there is an interest in com-
ining more than one scheme simultaneously. In most cases, this
ntegrative effort is propelled by the type of biological question to
e explored and the experimental technologies that can be used to
ssess the conclusions. Currently, some strategies have been pro-
osed to model metabolism in solid tumors by integrating different
evels of complexity, such as metabolism and tumor development
94,95]. Advances in these types of modeling will create the oppor-
unity to analyze the behavior of cancer cells with a greater level of
etail, including additional processes such as cell cycle, angiogen-
sis, metastasis and the effect of metabolite gradients during the
rowth of solid tumors [95,96].
Overall, these paradigms constitute a valuable conceptual plat-
orm to characterize, understand and identify the mechanisms
ustaining cancer [43,97]. As soon as these approaches increase
heir capacity to integrate biological information and heteroge-
eous high-throughput data, their role for moving toward an
ntegrative analysis of diseases and the development of person-
lized, preventive and predictive medicine will become evident in
linical areas.
. Tissue speciﬁc metabolism in cancer
Metabolic alterations are important avenues to propitiate
umorigenesis and sustain cancer, these changes are heavily inﬂu-
nced by the physiological and microenvironmental conditions
n human tissues. The human body integrates tissues with cells
hat are specialized in several processes, such as storing fat, trans-
orming carbohydrates, creating hormones and covering energetic
emands, among others functions. Tissues have physiological pur-
oses, and when a disease emerges, its evolution is strongly
nﬂuenced by tissue-speciﬁc metabolic ambiance [32,46,96,98]. For
nstance, prostate cancer appears to prefer fatty acid metabolism
s a source of acetyl-CoA synthesis, whereas breast cancer appears
o prefer the consumption of glucose as a main carbon source to
ustain malignant phenotype [99,100]. Undoubtedly, the charac-
erization of speciﬁc metabolic states in each tissue will contribute
o improve the descriptive and predictive capacities of com-
utational models in different types of cancer. To address this
aluable and fundamental topic, there have been efforts to cre-
te manually curated networks (bottom-up scheme) for a couple
f human tissues [101–104]. This type of reconstruction has the
dvantage of including high-quality curated information regarding
iological networks. In recent years there has also been increased
nterest in implementing computational algorithms that integrate Cancer Biology 30 (2015) 79–87 85
high-throughput data to reconstruct tissue-speciﬁc metabolic
networks (top-down scheme). In the latter case, these compu-
tational methods start from a generic non-tissue-speciﬁc human
metabolic reconstruction – such as Recon [55,56,100], EHMN [105]
or HumanCyc [106] – and then select the subnetwork that bet-
ter ﬁts available biological data, such as microarrays, proteomics
or metabolomics. Currently, a variety of methods are available in
the literature, some of which have been applied to reconstruct the
tissue-speciﬁc metabolism in cancer [38,107]. Conceptual foun-
dations and properties of some of these methods are brieﬂy
described in Table 2. Some differences can be highlighted among
them, for instance, INIT (Integrative Network Inference for Tis-
sues) allows for a small net accumulation in the metabolic ﬂux
to have a network able to synthesize molecules such as NADH,
rather than only being able to use such molecules as cofactors
[108]. Although the ﬁnal tissue-speciﬁc metabolic reconstruction
in mCADRE (context-speciﬁcity assessed by deterministic reac-
tion evaluation) is constrained to produce universally important
metabolites from simple precursors such as glucose, INIT allows
the model to use precursors that the cell is known to take up [109].
Remarkably, the achievements of these methods constitute a ﬁrst
step toward a human metabolic atlas that will serve as a platform
to understand the metabolic alterations in cancer and potentially
design drugs and more effective treatments for patients.
4. Outlook
Mathematical models represent a simpliﬁed version of real-
ity whose essential purpose is to help us handle and understand
the complexity of biological phenomena. Systems biology enables
the systematic analysis and coherent interpretation of high-
throughput data, and this paradigm is fundamental to achieve a
better understanding of metabolic mechanisms involved in can-
cer in a coherent and systematic fashion. The implications of this
perspective should be reﬂected in practical aims oriented toward
basic questions in biomedical sciences and clinical areas, such
as the uncovering of metabolic alterations in cancer, discovering
possible therapeutic targets or properly designing personalized
treatments. However, these aims are not trivial tasks, and one
important piece in the puzzle is the development of computational
modeling methods that are capable of integrating information
with HT data and physiological behavior in cancer. In this review,
we present some theoretical schemes that have contributed to
the understanding of key mechanisms in cancer. Each approach,
whether mathematically or computationally, has its own scopes
that are distinguished by their levels of complexity and the num-
ber of variables used to model the phenotype. Thus, systems biology
schemes are a paradigm to advance our knowledge of how can-
cer emerges in tissues and how to design novel drugs treatments.
Although there have been some important advances in this area, the
practical implication of these ﬁndings for cancer therapy remains
a challenge in systems biology. This challenges addresses addi-
tional problems, such as the building of a common language to
communicate between the clinical and theoretical scientists and
preparing a new generation of scientists with skills in mathematics,
genomic and computational sciences. In our opinion, these strate-
gies are required to move toward a quantitative description of
cancer phenotype that contributes to the advent of a systemic and
personalized medicine.Funding
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